| | | 占用方与上 | 上市公司核算的 | 2023 年期初占 | 2023 年半年度占 | 2023 年半年度 | 2023 年半年度 | 2023 年 | 6 月末 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 市公司的关 | | | 用累计发生金额 | 占用资金的利 | 偿还累计发生 | | | | 占用性质 | | | | 联关系 | 会计科目 | 用资金余额 | （不含利息） | 息（如有） | 金额 | 占用资金余额 | | 原因 | | | 控股股东、实际控制人及 | - | - | - | - | - | - | - | - | | - | 非经营性 | | 其附属企业 | - | - | - | - | - | - | - | - | | - | 非经营性 | | 小计 | - | - | - | - | - | - | - | - | | - | - | | 前控股股东、实际控制人 | - | - | - | - | ...

证券代码：301122 证券简称：采纳股份 公告编号：2023-071 采纳科技股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 单位：人民币万元 | | 项目 | | 序号 | 金额 | | --- | --- | --- | --- | --- | | 募集资金净额 | | A | | 109,726.24 | | 置换前期投入项目金额 | | B | 386.63 | | --- | --- | --- | --- | | 本期发生额 | 项目投入 | C1 | 8,803.33 | | | 永久补充流动资金划出金额 | C2 | 20,000.00 | | | 利息收入净额 | C3 | 943.76 | | 以前年度发生额 | 项目投入 | D1 | 12,134.07 | | | 永久补充流动资金划出金额 | D2 | 25,000.00 | | | 利息收入净额 | D3 | 1,400.58 | | 截至期末发生额 | 项目投入 | E1=B+C1+D1 | 21,324.03 | ...

Group 1: Project Progress and Capacity - The second phase project is located on Chenglu Road in Huashi Town, covering a planned area of 90,000 square meters, with the main structure completed and currently in the decoration phase. Some equipment has begun to arrive for installation and debugging. It is expected that part of the capacity will be released in the second half of 2023 [1] - After the capacity release of the second phase project, the company's product orders are expected to match. The product range includes three main sectors: medical devices, animal devices, and laboratory consumables [1] Group 2: Product Development and Market Position - The company has obtained a total of 27 FDA510K product registrations, ranking among the top in the domestic injection and puncture industry. Recently, the company passed FDA review and gained market access for a pen needle product, which can be used generally, not limited to insulin injection [3] - The company’s products cover a wide variety of categories and are continuously developed to meet customer needs. The customer base consists of globally recognized medical enterprises, establishing stable long-term cooperation [3] Group 3: Automation and Production Efficiency - The company is one of the early adopters of automated robotic storage systems and intelligent sterilization production lines in the country. The automation level of production is expected to further improve with the launch of the second phase project [3] Group 4: Financial Performance and Risks - The company's performance in the first quarter of this year declined year-on-year, primarily due to a temporary decrease in market demand and the impact of the Spring Festival holiday [4] - Exchange rate fluctuations primarily affect the company's export product pricing competitiveness and foreign exchange gains and losses. The company plans to enhance R&D investment and utilize financial tools to mitigate foreign exchange risk [4]

Financial Performance - The company's revenue for Q1 2023 was ¥66,839,280.56, representing a decrease of 52.79% compared to ¥141,589,832.60 in the same period last year[5] - Net profit attributable to shareholders was ¥15,878,407.77, down 59.62% from ¥39,324,380.01 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 66,839,280.56, a decrease of 52.8% compared to CNY 141,589,832.60 in the same period last year[19] - Net profit for Q1 2023 was CNY 15,878,407.77, a decline of 59.6% compared to CNY 39,324,380.01 in Q1 2022[20] - The total comprehensive income for the first quarter was CNY 15,878,407.77, a decrease from CNY 39,324,380.01 in the previous period[21] - Basic and diluted earnings per share for the quarter were both CNY 0.17, down from CNY 0.46 in the previous period[21] Cash Flow and Assets - The net cash flow from operating activities increased significantly to ¥38,212,822.55, a 5,374.04% improvement from -¥724,544.89 in the previous year[5] - The total cash and cash equivalents at the end of Q1 2023 amounted to CNY 282,245,196.54, down from CNY 355,590,390.56 at the beginning of the year, representing a decrease of approximately 20.5%[15] - The ending balance of cash and cash equivalents was CNY 282,245,196.54, down from CNY 802,495,998.92 in the previous period[23] - Cash inflow from investment activities totaled CNY 377,945,720.28, compared to CNY 100,200,000.00 in the previous period[23] - Cash outflow from investment activities was CNY 487,061,256.80, down from CNY 527,604,403.50 in the previous period[23] - The net cash flow from investment activities was negative CNY 109,115,536.52, an improvement from negative CNY 427,404,403.50 in the previous period[23] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,847,147,895.30, a slight increase of 0.20% from ¥1,843,375,847.83 at the end of the previous year[5] - Total liabilities decreased to CNY 94,926,248.64 from CNY 107,032,608.94, indicating a reduction in financial obligations[17] - The company's total equity increased to CNY 1,752,221,646.66 from CNY 1,736,343,238.89, showing a positive trend in shareholder value[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 6,109, with the top shareholder holding 28.29% of the shares[10] - The top shareholder, Jiangyin New Guolian Group Co., Ltd., holds 3,157,900 shares, representing 3.36% of the total shares[12] - The company has a total of 10 major shareholders, with the largest holding being 6,000,000 shares by Zhao Hong, accounting for 6.38%[12] Investment and Expenses - The company reported a significant increase in investment income, which rose by 2,056.02% to ¥6,568,470.28, attributed to returns from newly purchased financial products[9] - The company experienced a 601.03% increase in financial expenses, totaling ¥1,067,454.17, mainly due to increased foreign exchange losses[9] - Research and development expenses were CNY 4,784,955.79, slightly down from CNY 4,889,125.57 in the previous year[20] Future Outlook and Strategy - The company has not provided specific future outlook or performance guidance for the upcoming quarters[14] - The company plans to focus on market expansion and new product development as part of its future strategy[20] Other Information - The company has not disclosed any new product developments or technological advancements during this quarter[14] - There are no updates on market expansion or mergers and acquisitions in the current report[14] - The first quarter report was not audited[24]

Financial Performance - The company's operating revenue for 2022 was ¥465,485,537.41, representing a 5.30% increase compared to ¥442,051,932.24 in 2021[21]. - Net profit attributable to shareholders for 2022 was ¥161,868,649.81, a 23.86% increase from ¥130,681,695.99 in 2021[21]. - The net profit after deducting non-recurring gains and losses was ¥139,054,676.08, up 10.92% from ¥125,366,249.94 in 2021[21]. - The total assets at the end of 2022 reached ¥1,843,375,847.83, a significant increase of 200.90% from ¥612,622,396.12 at the end of 2021[21]. - The net assets attributable to shareholders increased by 240.38% to ¥1,736,343,238.89 from ¥510,124,479.38 in 2021[21]. - The company reported a basic earnings per share of ¥1.76, down 4.86% from ¥1.85 in 2021[21]. - The weighted average return on equity decreased to 10.28% from 29.38% in 2021, a decline of 19.10%[21]. - The company experienced a net cash flow from operating activities of ¥138,881,985.74, which is a decrease of 13.23% compared to ¥160,053,823.98 in 2021[21]. Market Position and Industry Insights - The company is positioned in the specialized equipment manufacturing industry, focusing on medical devices, animal instruments, and laboratory consumables[30]. - The global market for injection and puncture products is projected to grow from $14.58 billion in 2019 to $25.7 billion by 2026, with a compound annual growth rate of 8.5%[32]. - The global veterinary vaccine sales reached approximately $6.935 billion in 2018, with a year-on-year growth of 5.11%[35]. - The global veterinary injection and puncture device market grew from $2.65 billion in 2014 to $3.37 billion in 2019, with a compound annual growth rate (CAGR) of 5.0%[35]. - The Chinese veterinary injection and puncture device market increased from ¥1.76 billion in 2014 to ¥2.47 billion in 2019, with a CAGR of 7.0%[36]. - The market size of China's veterinary injection device market is expected to reach ¥3.51 billion by 2024[36]. - The global laboratory consumables market grew from $28.341 billion in 2016 to $51.233 billion in 2021, with an expected annual growth rate of 15%[39]. - The company holds a leading position in the domestic veterinary injection device market, ranking first with a significant market share in 2019[42]. Research and Development - The company has established a research and development system focused on market needs, with dedicated centers for veterinary puncture devices and safety self-destruct syringes[62]. - The company is developing a safety indwelling needle aimed at reducing patient discomfort and preventing the spread of bloodborne diseases, with product molds already completed and CE registration in progress[87]. - A safety structure syringe is under development, designed to prevent accidental injuries and improve product competitiveness, with design and sample production phases ongoing[87]. - The company has obtained 26 FDA 510K registrations for its products, leading the industry in this regard[90]. - The company's R&D investment reached CNY 19,733,928.29 in 2022, accounting for 4.24% of its operating revenue[89]. - The number of R&D personnel increased to 118 in 2022, representing a growth of 18.07% compared to 2021[89]. Production and Quality Control - The company maintains a strict quality control process throughout production, adhering to ISO13485 and FDA standards[52]. - The company has established a comprehensive quality management system, certified by ISO13485 and MDSAP[64]. - The company has a production facility exceeding 68,000 square meters, with over 40,000 square meters meeting GMP standards[67]. - The company emphasizes a production model based on customer orders, adopting a "sales-driven production" approach to ensure product quality and efficiency[52]. Cash Flow and Investment Activities - The total cash inflow from operating activities in 2022 was approximately ¥512.06 million, an increase of 8.19% compared to ¥473.28 million in 2021[98]. - The total cash outflow from operating activities in 2022 was approximately ¥373.18 million, representing a 19.14% increase from ¥313.23 million in 2021[98]. - The cash inflow from investment activities surged to approximately ¥1.35 billion in 2022, a dramatic increase of 14,052.37% compared to ¥9.52 million in 2021[98]. - The cash outflow from investment activities in 2022 was approximately ¥2.34 billion, a significant rise of 1,545.29% from ¥142.15 million in 2021[98]. - The net cash flow from investment activities was approximately -¥991.91 million in 2022, worsening from -¥132.64 million in 2021, indicating a 647.84% increase in negative cash flow[98]. Governance and Compliance - The company emphasizes information disclosure, adhering to legal requirements to provide accurate and timely information to all shareholders[144]. - The company maintains an independent governance structure, ensuring operational independence from its controlling shareholder and actual controller[143]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[140]. - The supervisory board is composed of 3 members, including 1 employee representative, fulfilling its responsibilities to protect shareholder interests[142]. Employee Management and Compensation - The total number of employees at the end of the reporting period was 689, with 352 in the parent company and 337 in major subsidiaries[182]. - The company has a competitive salary policy, combining base salary and performance-based pay, with salaries determined by job importance and company performance[184]. - The company plans to attract high-level technical, management, and marketing talents through competitive compensation and training programs over the next three years[185]. - The total pre-tax remuneration for directors, supervisors, and senior management amounted to CNY 3.0655 million[172]. Future Strategies and Goals - The company plans to increase R&D investment to enhance product competitiveness and profitability, aiming to mitigate risks from potential trade tensions and tariffs[128]. - The company aims to expand its product offerings and enhance competitiveness through innovative R&D initiatives[88]. - The company is focused on expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[175]. - The company plans to enhance its online sales platform, aiming for a 40% increase in e-commerce revenue in 2023[175].

证券代码：301122 证券简称：采纳股份 公告编号：2023-025 采纳科技股份有限公司 关于举办 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 11 日在巨潮 资讯网上披露了《2022 年年度报告全文》及《2022 年年度报告摘要》。为便于 广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 04 月 20 日（星期四）15:00-17:00 在"价值在线"（www.ir-online.cn）举办 公司 2022 年度业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见 和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2023 年 04 月 20 日（星期四）15:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 出席本次年度业绩说明会的人员：董事长兼总经理陆军先生、董事会秘书陆 维炜先生、财务负责人查凌云女士、独立董事刘斌先生、保荐代表人钟 ...

证券代码：301122 证券简称：采纳股份 编号：2022-01 采纳科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | ■特定对象调研 □分析师会议 □媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | ■现场参观 □其他 （请文字说明其他活动内容） | | | | 华创证券：郑辰、李婵娟 人保资产：蔡春根 | | | | 博时基金：张弘 | 天风证券：杨松、张雪 | | | 招商证券：孙炜、许菲菲 | 汇添富基金：张韡、谢杰 | | | | 中泰证券：彭婷 宝盈基金：姚艺、刘迪 | | 参与单位名称及 | 中欧基金：王建礼、任逸哲 大成基金：陈泉龙 | | | 人员姓名 | 景顺长城：姜雪婷、詹成 | 交银施罗德：朱亦宁 | | | 兴全基金：隋毅 东方红 ...

1 / 6 证券代码：301122 证券简称：采纳股份 采纳科技股份有限公司 投资者关系活动记录表 编号：2022-03 | --- | --- | --- | --- | |---------------------|-----------------------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------------------------------| | 投资者关系活动 类别 | ■特定对象调研 | ■分析师会议 □媒体采访 \n□业绩说明会 □新闻发布会 \n■现场参观 ■其他（电话会议） | □路演活动 | | 参与单位名称及 | 86 家机构参与，详见附件清单。 | | | | 人员姓名 | | | | | 时间 | 2022 年 8 月 25 日-8 | 月 31 日 | | | 地点 | 公司会议室 | | | | 上市公 ...